SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jensen OM, Esteve J, Moller H, Renard H. Cancer in the European Community and its member states. Eur J Cancer 1990; 26: 1167256
  • 2
    Coebergh J. Incidence and Prognosis of Cancer in The Netherlands: Studies Based on Cancer Registries. Doctoral Thesis. Rotterdam: Erasmus University, 1991
  • 3
    Wang MVL, Murphy GP, Chu TM. Purification of a human prostate-specific antigen. Invest Urol 1979; 17: 15963
  • 4
    Catalona WJ, Smith DS, Ratliff TL et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 115661
  • 5
    IPSTEG. Rationale for randomised trials of prostate cancer screening. Eur J Cancer 1999; 35: 26271
  • 6
    Schröder FH, Denis LJ, Kirkels W, De Koning HJ, Standaert B. European randomized study of screening for prostate cancer. Progress report of Antwerp and Rotterdam pilot studies. Cancer 1995; 76: 12934
  • 7
    Schröder F. Prostate cancer: to screen or not to screen? BMJ 1993; 306: 4078
  • 8
    Schröder FH, Damhuis RA, Kirkels WJ et al. European randomized study of screening for prostate cancer, the Rotterdam pilot studies. Int J Cancer 1996; 65: 14551
  • 9
    Auvinen A, Rietbergen JB, Denis LJ, Schröder FH, Prorok PC. Prospective evaluation plan for randomised trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group. J Med Screen 1996; 3: 97104
  • 10
    Nijs HG, Tordoir DM, Schuurman JH, Kirkels WJ, Schröder FH. Randomised trial of prostate cancer screening in The Netherlands: assessment of acceptance and motives for attendance. J Med Screen 1997; 4: 1026
  • 11
    Bangma CH, Kranse R, Blijenberg BG, Schröder FH. The value of screening tests in the detection of prostate cancer. Part I: Results of a retrospective evaluation of 1726 men. Urology 1995; 46: 7738
  • 12
    Bangma CH, Kranse R, Blijenberg BG, Schröder FH. The value of screening tests in the detection of prostate cancer. Part II: Retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density. Urology 1995; 46: 77984
  • 13
    Rietbergen JB, Kranse R, Kirkels WJ, De Koning HJ, Schröder FH. Evaluation of prostate-specific antigen, digital rectal examination and transrectal ultrasonography in population-based screening for prostate cancer: improving the efficiency of early detection. Br J Urol 1997; 79: 5763
  • 14
    Rietbergen JB, Kruger AE, Hoedemaeker RF, Bangma CH, Kirkels WJ, Schröder FH. Repeat screening for prostate cancer after 1-year follow-up in 984 biopsied men: clinical and pathological features of detected cancer. J Urol 1998; 160: 21215
  • 15
    Schröder FH, Van Der Maas P, Beemsterboer P et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 1998; 90: 181723
  • 16
    Beemsterboer PM, Kranse R, De Koning HJ, Habbema JD, Schröder FH. Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam). Int J Cancer 1999; 84: 43741
  • 17
    Kranse R, Beemsterboer P, Rietbergen J, Habbema D, Hugosson J, Schröder FH. Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region). Prostate 1999; 39: 31622
  • 18
    Hoedemaeker RF, Rietbergen JB, Kranse R, Van Der Kwast TH, Schröder FH. Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer. World J Urol 1997; 15: 33945
  • 19
    Vis AN, Hoedemaeker RF, Roobol M, Van Der Kwast TH, Schröder FH. Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0–3.9 ng/ml). Prostate 2001; 47: 25261
  • 20
    Schröder FH, Roobol-Bouts M, Vis AN, Van Der Kwast TH, Kranse R. Prostate-specific antigen-based early detection of prostate cancer – validation of screening without rectal examination. Urology 2001; 57: 8390
  • 21
    Van Der Cruijsen IW, Van Der Kwast TH, Schröder FH. Interval carcinomas in the European Randomised Study of Screening for Prostate Cancer (ERSPC) − section Rotterdam. JNCI 2003; 95(19): 14626
  • 22
    Schröder FH, Van Der Cruijsen-Koeter I, De Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol 2000; 163: 80612
  • 23
    Roobol MJ, Kranse R, Schröder FH. The value of PSA velocity as a screening tool for prostate cancer at low PSA levels (i.e. PSA <4 ng/ml). Results of the second screening round of ERSPC (Rotterdam). Urology 2003, in press
  • 24
    Raaijmakers R, Blijenberg BA, Finlay JA, Rittenhouse H, Roobol MJ, Schröder FH. Prostate cancer (PC) detection in the PSA range 2–4 ng/ml, value of PSA, fPSA, hK2 and related algorithms. Urology 2003; in press